BTP-661411

BTP-661411 is an investigational agent referenced in the context of treatments for **EGFR C797S mutation-positive non-small cell lung cancer (NSCLC)**. It is mentioned alongside other investigational and marketed agents for patients with EGFR mutations, specifically in relation to resistance mutations such as C797S, but no public clinical mechanism, molecular type, or additional information has been disclosed in the available trial documentation. The drug does not appear to have completed late-stage clinical development or progressed to approval; its precise structure, mechanism of action, developer, or clinical trial outcomes are not described in public domain literature as of the current date[1][3][5].